The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review

S Ryder, R M Leadley, N Armstrong, M Westwood, S de Kock, T Butt, M Jain, J Kleijnen, S Ryder, R M Leadley, N Armstrong, M Westwood, S de Kock, T Butt, M Jain, J Kleijnen

Abstract

Background: Duchenne Muscular Dystrophy (DMD) is a rapidly progressive, lethal neuromuscular disorder, present from birth, which occurs almost exclusively in males. We have reviewed contemporary evidence of burden, epidemiology, illness costs and treatment patterns of DMD. This systematic review adhered to published methods with information also sought from the web and contacting registries. Searches were carried out from 2005 to June 2015. The population of interest was individuals with clearly defined DMD or their carers.

Results: Nine thousand eight hundred fifty titles were retrieved from searches. Fifty-eight studies were reviewed with three assessed as high, 33 as medium and 22 as low quality. We found two studies reporting birth and four reporting point prevalence, three reporting mortality, 41 reporting severity and/or progression, 18 reporting treatment patterns, 12 reporting quality of life, two reporting utility measures, three reporting costs of illness and three treatment guidelines. Birth prevalence ranged from 15.9 to 19.5 per 100,000 live births. Point prevalence per 100,000 males was for France, USA, UK and Canada, 10.9, 1.9, 2.2 and 6.1 respectively. A study of adult DMD patients at a centre in France found median survival for those born between 1970 and 1994 was 40.95 years compared to 25.77 years for those born between 1955 and 1969. Loss of ambulation occurred at a median age of 12 and ventilation starts at about 20 years. There was international variation in use of corticosteroids, scoliosis surgery, ventilation and physiotherapy. The economic cost of DMD climbs dramatically with disease progression - rising as much as 5.7 fold from the early ambulatory phase to the non-ambulatory phase in Germany.

Conclusions: This is the first systematic review of treatment, progression, severity and quality of life in DMD. It also provides the most recent description of the burden, epidemiology, illness costs and treatment patterns in DMD. There are evidence gaps, particularly in prevalence and mortality. People with DMD seem to be living longer, possibly due to corticosteroid use, cardiac medical management and ventilation. Future research should incorporate registry data to improve comparability across time and between countries and to investigate the quality of life impact as the condition progresses.

Keywords: Burden; Cost; DMD; Duchenne; Epidemiology; Incidence; Prevalence.

Figures

Fig. 1
Fig. 1
Flow diagram of included studies
Fig. 2
Fig. 2
Variation in corticosteroid use

References

    1. Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381(9869):845–860. doi: 10.1016/S0140-6736(12)61897-2.
    1. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, Kneile K, Dunn DM, Duval B, Aoyagi A, Hamil C, Mahmoud M, Roush K, Bird L, Rankin C, Lilly H, Street N, Chandrasekar R, Weiss RB. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71(3):304–13. doi: 10.1002/ana.23528.
    1. Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK) Eur J Hum Genet. 2013;21(10):1049–53. doi: 10.1038/ejhg.2012.301.
    1. Magri F, Govoni A, D’Angelo MG, Del Bo R, Ghezzi S, Sandra G, Turconi AC, Sciacco M, Ciscato P, Bordoni A, Tedeschi S, Fortunato F, Lucchini V, Bonato S, Lamperti C, Coviello D, Torrente Y, Corti S, Moggio M, Bresolin N, Comi GP. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol. 2011;258(9):1610–23. doi: 10.1007/s00415-011-5979-z.
    1. Davidson ZE, Ryan MM, Kornberg AJ, Sinclair K, Cairns A, Walker KZ, Truby H. Observations of body mass index in Duchenne muscular dystrophy: a longitudinal study. Eur J Clin Nutr. 2014;68(8):892–7. doi: 10.1038/ejcn.2014.93.
    1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, Group DMDCCW. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93. doi: 10.1016/S1474-4422(09)70271-6.
    1. Higgins JPT, Green S, editors, Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration. 2011. Available from: . Accessed 23 Mar 2011.
    1. Centre for Reviews and Dissemination . Systematic Reviews: CRD’s guidance for undertaking reviews in health care. York: University of York; 2009.
    1. Canadian Agency for Drugs and Technologies in Health . CADTH peer review checklist for search strategies. Ottawa: CADTH; 2013.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9. doi: 10.1016/j.jclinepi.2007.11.008.
    1. Kinnett K, Rodger S, Vroom E, Furlong P, Aartsma-Rus A, Bushby K. Imperatives for Duchenne MD: a simplified guide to comprehensive care for Duchenne muscular dystrophy. PLoS Curr. 2015;7. .
    1. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132(Pt 11):3175–86. doi: 10.1093/brain/awp236.
    1. Rasmussen M, Risberg K, Vollo A, Skjeldal OH. Neuromuscular disorders in children in south-eastern Norway. J Pediatr Neurol. 2012;10(2):95–100.
    1. Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, Ciafaloni E, Cunniff C, Druschel CM, Mathews KD, Matthews DJ, Meaney FJ, Andrews JG, Conway KM, Fox DJ, Street N, Adams MM, Bolen J, STARnet MD Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics. 2015;135(3):513–21. doi: 10.1542/peds.2014-2044.
    1. Mah JK, Selby K, Campbell C, Nadeau A, Tarnopolsky M, McCormick A, Dooley JM, Kolski H, Skalsky AJ, Smith RG, Buckley D, Ray PN, Yoon G. A population-based study of dystrophin mutations in Canada. Can J Neurol Sci. 2011;38(3):465–74. doi: 10.1017/S0317167100011896.
    1. Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, Roy A, Chamova T, Guergueltcheva V, Korngut L, Campbell C, Dai Y, Barisic N, Kos T, Brabec P, Rahbek J, Lahdetie J, Tuffery-Giraud S, Claustres M, Leturcq F, Ben Yaou R, Walter MC, Schreiber O, Karcagi V, Herczegfalvi A, Viswanathan V, Bayat F, de la Caridad Guerrero Sarmiento I, Ambrosini A, Ceradini F, et al. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat. 2013;34(11):1449–57. doi: 10.1002/humu.22390.
    1. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, Perrouin Verbe B. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013;56(6):443–54. doi: 10.1016/j.rehab.2013.06.002.
    1. Passamano L, Taglia A, Palladino A, Viggiano E, D’Ambrosio P, Scutifero M, Rosaria Cecio M, Torre V, DE Luca F, Picillo E, Paciello O, Piluso G, Nigro G, Politano L. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31(2):121–5.
    1. Rall S, Grimm T. Survival in Duchenne muscular dystrophy. Acta Myol. 2012;31(2):117–20.
    1. Kieny P. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011, Evolution de l’esperance de vie des patients atteints de dystrophie musculaire de Duchenne au centre AFM Yolaine de Kepper entre 1981 et 2011. [French, English] Paper presented at 27e Congrès de Médecine Physique et de Réadaptation; 19–20 Oct 2012; Toulouse: France. Ann Phys Rehabil Med. 2012;55:e204–e206. doi: 10.1016/j.rehab.2012.07.516.
    1. Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, de Bie E, McDonald CM: The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr. 2013;5. .
    1. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, Glanzman AM, Group PG-DS, Spiegel R, Barth J, Elfring G, Reha A, Peltz S. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013;48(3):343–56. doi: 10.1002/mus.23902.
    1. Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, Nagels KH, Walter MC. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9:210. doi: 10.1186/s13023-014-0210-9.
    1. Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens PR, Investigators C. Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve. 2014;50(2):250–6. doi: 10.1002/mus.24163.
    1. Bello L, Kesari A, Gordish-Dressman H, Cnaan A, Morgenroth LP, Punetha J, Duong T, Henricson EK, Pegoraro E, McDonald CM, Hoffman EP, Cooperative International Neuromuscular Research Group I Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study. Ann Neurol. 2015;77(4):684–96. doi: 10.1002/ana.24370.
    1. Nakamura H, Kimura E, Mori-Yoshimura M, Komaki H, Matsuda Y, Goto K, Hayashi YK, Nishino I, Takeda S, Kawai M. Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy) Orphanet J Rare Dis. 2013;8:60. doi: 10.1186/1750-1172-8-60.
    1. Mayer OH, Finkel RS, Rummey C, Benton MJ, Glanzman AM, Flickinger J, Lindstrom BM, Meier T. Characterization of pulmonary function in Duchenne muscular dystrophy. Pediatr Pulmonol. 2015;50(5):487–94. doi: 10.1002/ppul.23172.
    1. Martigne L, Salleron J, Mayer M, Cuisset JM, Carpentier A, Neve V, Tiffreau V, Guimber D, Gottrand F. Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit. Br J Nutr. 2011;105(10):1486–91. doi: 10.1017/S0007114510005180.
    1. de Moura MC, Wutzki HC, Voos MC, Resende MB, Reed UC, Hasue RH. Is functional dependence of Duchenne muscular dystrophy patients determinant of the quality of life and burden of their caregivers? Arq Neuropsiquiatr. 2015;73(1):52–7. doi: 10.1590/0004-282X20140194.
    1. Magri F, Del Bo R, D’Angelo MG, Govoni A, Ghezzi S, Gandossini S, Sciacco M, Ciscato P, Bordoni A, Tedeschi S, Fortunato F, Lucchini V, Cereda M, Corti S, Moggio M, Bresolin N, Comi GP. Clinical and molecular characterization of a cohort of patients with novel nucleotide alterations of the Dystrophin gene detected by direct sequencing. BMC Med Genet. 2011;12:37. doi: 10.1186/1471-2350-12-37.
    1. Lorusso ML, Civati F, Molteni M, Turconi AC, Bresolin N, D’Angelo MG. Specific profiles of neurocognitive and reading functions in a sample of 42 Italian boys with Duchenne muscular dystrophy. Child Neuropsychol. 2013;19(4):350–69. doi: 10.1080/09297049.2012.660912.
    1. Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, Habeeb-Louks EM, Kennedy A, Cwik VA. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49(3):431–8. doi: 10.1002/mus.23942.
    1. Selsby JT. Increased catalase expression improves muscle function in mdx mice. Exp Physiol. 2011;96(2):194–202. doi: 10.1113/expphysiol.2010.054379.
    1. Pane M, Mazzone ES, Sivo S, Sormani MP, Messina S, D’Amico A, Carlesi A, Vita G, Fanelli L, Berardinelli A, Torrente Y, Lanzillotta V, Viggiano E, DA P, Cavallaro F, Frosini S, Barp A, Bonfiglio S, Scalise R, De Sanctis R, Rolle E, Graziano A, Magri F, Palermo C, Rossi F, Donati MA, Sacchini M, Arnoldi MT, Baranello G, Mongini T, et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One. 2014;9(10):e108205. doi: 10.1371/journal.pone.0108205.
    1. Khirani S, Ramirez A, Aubertin G, Boule M, Chemouny C, Forin V, Fauroux B. Respiratory muscle decline in Duchenne muscular dystrophy. Pediatr Pulmonol. 2014;49(5):473–81. doi: 10.1002/ppul.22847.
    1. Janssen MM, Bergsma A, Geurts AC, de Groot IJ. Patterns of decline in upper limb function of boys and men with DMD: an international survey.[Erratum appears in J Neurol. 2014 Jul;261(7):1289–90]. J Neurol. 2014;261(7):1269–88.
    1. Ashwath ML, Jacobs IB, Crowe CA, Ashwath RC, Super DM, Bahler RC. Left ventricular dysfunction in duchenne muscular dystrophy and genotype. Am J Cardiol. 2014;114(2):284–9. doi: 10.1016/j.amjcard.2014.04.038.
    1. Thomas TO, Morgan TM, Burnette WB, Markham LW. Correlation of heart rate and cardiac dysfunction in Duchenne muscular dystrophy. Pediatr Cardiol. 2012;33(7):1175–9. doi: 10.1007/s00246-012-0281-0.
    1. Rodger S, Woods KL, Bladen CL, Stringer A, Vry J, Gramsch K, Kirschner J, Thompson R, Bushby K, Lochmuller H. Adult care for Duchenne muscular dystrophy in the UK. J Neurol. 2015;262(3):629–41. doi: 10.1007/s00415-014-7585-3.
    1. Vry J, Gramsch K, Bushby K, Lochmuller H, Rodger S, Steffensen B, Rahbek J, Kirschner J: Current care practice in Duchenne muscular dystrophy in Europe-results of the CARE-NMD cross-sectional survey. Neuropediatrics. 2013;44(02):FV16_03.
    1. Connolly AM, Florence JM, Cradock MM, Malkus EC, Schierbecker JR, Siener CA, Wulf CO, Anand P, Golumbek PT, Zaidman CM, Philip Miller J, Lowes LP, Alfano LN, Viollet-Callendret L, Flanigan KM, Mendell JR, McDonald CM, Goude E, Johnson L, Nicorici A, Karachunski PI, Day JW, Dalton JC, Farber JM, Buser KK, Darras BT, Kang PB, Riley SO, Shriber E, Parad R, et al. Motor and cognitive assessment of infants and young boys with Duchenne muscular dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord. 2013;23(7):529–39. doi: 10.1016/j.nmd.2013.04.005.
    1. Pane M, Mazzone ES, Sormani MP, Messina S, Vita GL, Fanelli L, Berardinelli A, Torrente Y, D’Amico A, Lanzillotta V, Viggiano E, D’Ambrosio P, Cavallaro F, Frosini S, Bello L, Bonfiglio S, Scalise R, De Sanctis R, Rolle E, Bianco F, Van der Haawue M, Magri F, Palermo C, Rossi F, Donati MA, Alfonsi C, Sacchini M, Arnoldi MT, Baranello G, Mongini T, et al. 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS One. 2014;9(1):e83400. doi: 10.1371/journal.pone.0083400.
    1. Kota P, Aleksandrov AA, Riordan JR, Dokholyan NV. Dynamic coupling within NBD1 influences thermostability and function of CFTR. Pediatr Pulmonol. 2011;46:230. doi: 10.1002/ppul.21356.
    1. Mah JK, Hu F, McDonald CM, Research Group C Short stature prolonged ambulation in boys with Duchenne muscular dystrophy. Paper presented at the 47th Annual Congress of the Canadaian Neurological Sciences Federation; 5–8 Jun 2012; Ontario, Canada. Can J Neurol Sci. 2012;39(Suppl 3):S13.
    1. Soderpalm AC, Magnusson P, Ahlander AC, Karlsson J, Kroksmark AK, Tulinius M, Swolin-Eide D. Bone mass development in patients with Duchenne and Becker muscular dystrophies: a 4-year clinical follow-up. Acta Paediatr. 2012;101(4):424–32. doi: 10.1111/j.1651-2227.2011.02532.x.
    1. Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, Torrente Y, D’Amico A, Doglio L, Viggiano E, D’Ambrosio P, Cavallaro F, Frosini S, Bello L, Bonfiglio S, De Sanctis R, Rolle E, Bianco F, Magri F, Rossi F, Vasco G, Vita G, Motta MC, Donati MA, Sacchini M, Mongini T, Pini A, Battini R, Pegoraro E, Previtali S, et al.: 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy.[Erratum appears in PLoS One. 2013;8(11). doi:10.1371/annotation/cbe611fe-cda9-4d98-9574-0ac18e109daa]. PLoS One. 2013;8(1):e52512.
    1. Ricotti V, Manzur AY, Scott E, Muntoni F. Benefits and adverse effects of glucocorticoids in males with Duchenne muscular dystrophy: a UK perspective. Dev Med Child Neurol. 2012;54:14–15. doi: 10.1111/j.1469-8749.2011.04189.x.
    1. Fox DJ, Kumar A, West NA, DiRienzo AG, James KA, Oleszek J, Muscular Dystrophy Surveillance T. Research N Trends with corticosteroid use in males with Duchenne muscular dystrophy born 1982–2001. J Child Neurol. 2015;30(1):21–6. doi: 10.1177/0883073813517263.
    1. Pentek M, Baji P, Pogany G, Brodszky V, Boncz I, Gulacsi L. Health related quality of life of patients and their caregivers in rare diseases results of the BURQOL-RD project in Hungary. Value Health. 2014;17(7):A538. doi: 10.1016/j.jval.2014.08.1724.
    1. Lim Y, Velozo C, Bendixen RM. The level of agreement between child self-reports and parent proxy-reports of health-related quality of life in boys with Duchenne muscular dystrophy. Qual Life Res. 2014;23(7):1945–52. doi: 10.1007/s11136-014-0642-7.
    1. Bendixen RM, Lott DJ, Senesac C, Mathur S, Vandenborne K. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy. Disabil Rehabil. 2014;36(22):1918–23. doi: 10.3109/09638288.2014.883444.
    1. Uzark K, King E, Cripe L, Spicer R, Sage J, Kinnett K, Wong B, Pratt J, Varni JW. Health-related quality of life in children and adolescents with Duchenne muscular dystrophy. Pediatrics. 2012;130(6):e1559–66. doi: 10.1542/peds.2012-0858.
    1. Bendixen RM, Senesac C, Lott DJ, Vandenborne K. Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health. Health Qual Life Outcomes. 2012;10:43. doi: 10.1186/1477-7525-10-43.
    1. Pangalila RF, van den Bos GA, Bartels B, Bergen M, Stam HJ, Roebroeck ME. Prevalence of fatigue, pain, and affective disorders in adults with Duchenne muscular dystrophy and their associations with quality of life. Arch Phys Med Rehabil. 2015;96(7):1242–7. doi: 10.1016/j.apmr.2015.02.012.
    1. Simon VA, Resende MB, Simon MA, Zanoteli E, Reed UC. Duchenne muscular dystrophy: quality of life among 95 patients evaluated using the Life Satisfaction Index for Adolescents. Arq Neuropsiquiatr. 2011;69(1):19–22. doi: 10.1590/S0004-282X2011000100005.
    1. Baiardini I, Minetti C, Bonifacino S, Porcu A, Klersy C, Petralia P, Balestracci S, Tarchino F, Parodi S, Canonica GW, Braido F. Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol. 2011;26(6):707–13. doi: 10.1177/0883073810389043.
    1. Houwen-van Opstal SL, Jansen M, van Alfen N, de Groot IJ. Health-related quality of life and its relation to disease severity in boys with Duchenne muscular dystrophy: satisfied boys, worrying parents--a case–control study. J Child Neurol. 2014;29(11):1486–95. doi: 10.1177/0883073813506490.
    1. Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, Lochmuller H, Bushby K. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529–36. doi: 10.1212/WNL.0000000000000669.
    1. Birnkrant DJ, Bushby KM, Amin RS, Bach JR, Benditt JO, Eagle M, Finder JD, Kalra MS, Kissel JT, Koumbourlis AC, Kravitz RM. The respiratory management of patients with Duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol. 2010;45(8):739–48. doi: 10.1002/ppul.21254.
    1. McDonald CM, McDonald DA, Bagley A, Sienko Thomas S, Buckon CE, Henricson E, Nicorici A, Sussman MD. Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy. J Child Neurol. 2010;25(9):1130–44. doi: 10.1177/0883073810371509.
    1. Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, Jones K, Krishnamurthi R, Feigin V. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43(3–4):259–68. doi: 10.1159/000369343.
    1. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24(6):482–91. doi: 10.1016/j.nmd.2014.03.008.
    1. Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119(7):964–979. doi: 10.1016/j.healthpol.2014.12.016.
    1. TREAT-NMD Neuromuscular Network . Advancing diagnosis, care and treatment for those living with neuromuscular diseases around the world. 2015.
    1. Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Barisic N, Brabec P, Lahdetie J, Walter MC, Schreiber-Katz O, Karcagi V, Garami M, Viswanathan V, Bayat F, Buccella F, Kimura E, Koeks Z, van den Bergen JC, Rodrigues M, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36(4):395–402. doi: 10.1002/humu.22758.
    1. Kempen JC, Harlaar J, van der Kooi AJ, de Groot IJ, van den Bergen JC, Niks EH, Verschuuren JJ, Brehm MA. Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2014;24(3):216–21. doi: 10.1016/j.nmd.2013.11.015.
    1. Lerario A, Bonfiglio S, Sormani M, Tettamanti A, Marktel S, Napolitano S, Previtali S, Scarlato M, Natali-Sora M, Mercuri E, Bresolin N, Mongini T, Comi G, Gatti R, Ciceri F, Cossu G, Torrente Y. Quantitative muscle strength assessment in Duchenne muscular dystrophy: longitudinal study and correlation with functional measures. BMC Neurol. 2012;12:91. doi: 10.1186/1471-2377-12-91.
    1. McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, Duong T, Arrieta A, Clemens PR, Hoffman EP, Cnaan A, Cinrg I. The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48(1):32–54. doi: 10.1002/mus.23807.
    1. Roberto R, Fritz A, Hagar Y, Boice B, Skalsky A, Hwang H, Beckett L, McDonald C, Gupta M. The natural history of cardiac and pulmonary function decline in patients with Duchenne muscular dystrophy. Spine. 2011;36(15):E1009–17. doi: 10.1097/BRS.0b013e3181fea1ed.
    1. Sarrazin E, von der Hagen M, Schara U, von Au K, Kaindl AM. Growth and psychomotor development of patients with Duchenne muscular dystrophy. Europ J Paediatr Neurol. 2014;18(1):38–44. doi: 10.1016/j.ejpn.2013.08.008.
    1. Seferian AM, Moraux A, Annoussamy M, Canal A, Decostre V, Diebate O, Le Moing AG, Gidaro T, Deconinck N, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Maincent K, Desguerre I, Themar-Noel C, Cuisset JM, Tiffreau V, Denis S, Jousten V, Quijano-Roy S, Voit T, Hogrel JY, Servais L. Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne muscular dystrophy: an observational multicenter trial. PLoS One. 2015;10(2):e0113999. doi: 10.1371/journal.pone.0113999.
    1. West NA, Yang ML, Weitzenkamp DA, Andrews J, Meaney FJ, Oleszek J, Miller LA, Matthews D, DiGuiseppi C. Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J Pediatr. 2013;163(6):1759–1763.e1. doi: 10.1016/j.jpeds.2013.08.004.
    1. Pane M, Mazzone ES, Sivo S, Fanelli L, De Sanctis R, D’Amico A, Messina S, Battini R, Bianco F, Scutifero M, Petillo R, Frosini S, Scalise R, Vita GL, Bruno C, Pedemonte M, Mongini T, Pegoraro E, Brustia F, Gardani A, Berardinelli A, Lanzillotta V, Viggiano E, Cavallaro F, Sframeli M, Bello L, Barp A, Busato F, Bonfiglio S, Rolle E, et al. The 6 minute walk test and performance of upper limb in ambulant Duchenne muscular dystrophy boys. PLoS Curr. 2014;6.
    1. Mazzone E, Vasco G, Sormani MP, Torrente Y, Berardinelli A, Messina S, D’Amico A, Doglio L, Politano L, Cavallaro F, Frosini S, Bello L, Bonfiglio S, Zucchini E, De Sanctis R, Scutifero M, Bianco F, Rossi F, Motta MC, Sacco A, Donati MA, Mongini T, Pini A, Battini R, Pegoraro E, Pane M, Gasperini S, Previtali S, Napolitano S, Martinelli D, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology. 2011;77(3):250–6. doi: 10.1212/WNL.0b013e318225ab2e.
    1. Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, Elfring G, Reha A, Barth J, McDonald CM. Percent-predicted 6-minute walk distance in Duchenne muscular dystrophy to account for maturational influences. PLoS Curr. 2012;4:RRN1297. .

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren